Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance
Healthcare Logistics Provider Owens & Minor Calls Q2 Performance Consistent With Expectations, Reiterates Annual Guidance
On Friday, Owens & Minor Inc. (NYSE:OMI) reported that the second quarter of 2024 adjusted EPS of $0.36, double the $0.18 reported a year ago, beating the consensus of $0.33.
纽交所上市公司奥文斯与米纳公司（Owens & Minor Inc.）于周五发布2024年第二季度调整后的每股收益为0.36美元，是一年前的0.18美元的两倍，超过了0.33美元的共识预期。
The company reported sales of $2.671 billion, up 4% year-over-year, almost in line with the consensus of $2.646 billion.
该公司报告的销售额为26.71亿美元，同比增长4%，几乎与26.46亿美元的共识预期相符。
Patient Direct revenue of $660 million, up 4% compared to the second quarter of 2023, driven by continued strong growth in diabetes and sleep supplies.
直接患者销售收入为6600万美元，比2023年第二季度增长了4%，受糖尿病和睡眠用品需求的持续强劲增长带动。
Related: Healthcare Logistics Service Firm Owens & Minor To Buy Home-Based Care Equipment Firm For $1.4B, Sees Better Than Expected Q2 Earnings.
相关报道：医疗物流服务公司Owens & Minor以14亿美元收购家庭护理设备公司，并看好第二季度的业绩表现。
Products & Healthcare Services revenue of $2.0 billion, up 4% compared to the second quarter of 2023, driven by strong same-store sales and new wins in the Medical Distribution division.
产品和医疗服务收入为20亿美元，比2023年第二季度增长了4%，得益于同店销售额的增强以及医疗分配部门的新客户。
Operating income of $20.3 million and adjusted operating income of $76.3 million increased by 87% and 23%, respectively, in the second quarter of 2024.
2024年第二季度营业利润为2030万美元，调整后的营业利润为7630万美元，同比分别增长了87%和23%。
Adjusted EBITDA increased 12% to $127 million, with an operating cash flow of $116 million for the second quarter of 2024.
调整后的EBITDA增长了12％，至1.27亿美元，2024年第二季度的经营现金流为1.16亿美元。
"Our second-quarter performance is consistent with our expectations, as we are in the early stages of implementing our long-term strategy discussed at Investor Day in December 2023. Our previous investments in our Products & Healthcare Services segment yielded positive results and generated top-line growth in our Medical Distribution division. Our Patient Direct segment performed in line with our expectations, and we expect the segment to benefit from seasonality and recent organic investments during the back half of the year," said Edward Pesicka, President & CEO.
公司总裁兼首席执行官爱德华·佩西卡（Edward Pesicka）表示：“我们的第二季度业绩符合我们的预期，因为我们正在实施我们在2023年12月股东日上讨论的长期策略的早期阶段。我们以前在产品和医疗服务部门的投资产生了积极的结果，并为我们的医疗分配部门的营业收入增长提供了动力。我们的直接患者销售部门表现符合我们的预期，我们预计该部门将受益于全年后半段的季节性因素和最近的有机投资。”
Guidance: Owens & Minor reaffirms 2024 revenue guidance of $10.5 billion-$10.9 billion versus the consensus of $10.665 billion.
Owens & Minor重申2024年营业收入指引为105亿至109亿美元，而共识预期为106.65亿美元。
The company expects 2024 adjusted EPS of $1.40-$1.70 versus the consensus of $1.55.
该公司预计2024年每股调整后的收益为1.40美元至1.70美元，而共识预期为1.55美元。
Price Action: OMI stock was trading lower by 3.90% to $15.78 premarket at the last check on Friday.
截至周五上午，OMI股票预盘下跌3.90％至15.78美元。
- LabCorp's Stock Soars After Q2 Performance, Analyst Highlights Strong Position In Healthcare Sector.
- LabCorp第二季度表现出色，分析师强调其在医疗板块中的强势位置后其股票猛涨。